A

Antonio Lanzavecchia

Vir Biotechnology (Switzerland)

ORCID: 0000-0002-3041-7240

Publishes on T-cell and B-cell Immunology, Immune Cell Function and Interaction, Immunotherapy and Immune Responses. 542 papers and 112k citations.

PubIndex Score98Top 2%How it's scored

🌟#3 Current Senior Leader in Immunotherapy and Immune Responses 🌟#5 Current Senior Leader in T-cell and B-cell Immunology

542Publications

112kTotal Citations

#3in Immunotherapy and Immune Responses

First publication: 1980First senior author: 1977

T-cell and B-cell Immunology Immune Cell Function and Interaction Immunotherapy and Immune Responses Monoclonal and Polyclonal Antibodies Research SARS-CoV-2 and COVID-19 Research

Top publicationsby citations

L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity

Roger Geiger, Antonio Lanzavecchia|Cell|2016

Cited by 1.7k

Analysis of Memory B Cell Responses and Isolation of Novel Monoclonal Antibodies with Neutralizing Breadth from HIV-1-Infected Individuals

Davide Corti, Antonio Lanzavecchia|PLoS ONE|2010

Cited by 429

A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein

Joshua Tan, Antonio Lanzavecchia|Nature Medicine|2018

Cited by 227

Normal T lymphocytes can express two different T cell receptor beta chains: implications for the mechanism of allelic exclusion.

Elisabetta Padovan, Antonio Lanzavecchia|The Journal of Experimental Medicine|1995

Cited by 132